In August 2025, Sanofi acquired the rights to develop and commercialize Redemplo in Greater China from Visirna Therapeutics, a majority-owned subsidiary of Arrowhead Pharmaceuticals.
Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndromeUnderscores Sanofi's long-term commitment to ...
Once mosquitoes acquire a new food source, they tend to develop a preference for that particular blood—and humans are one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback